Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center National Institutes of Health (NIH) |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00664404 |
Objectives:
Condition | Intervention | Phase |
---|---|---|
Smoking |
Other: Functional Magnetic Resonance Imaging (fMRI) |
Phase III |
Study Type: | Interventional |
Study Design: | Basic Science, Open Label, Single Group Assignment |
Official Title: | Pharmacogenetics, Emotional Reactivity and Smoking Cessation: Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal |
Estimated Enrollment: | 72 |
Study Start Date: | April 2008 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1
Functional Magnetic Resonance Imaging (fMRI)
|
Other: Functional Magnetic Resonance Imaging (fMRI)
Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
|
Before you begin participation in this study, you will be asked to provide the names and addresses of 3 contacts (family member/friends) who will know your current contact information. This is so study researchers can stay in contact with you throughout the study. This is in case study researchers may need to reach you in order to reschedule your appointment time. You will also be asked to sign a letter giving your contacts permission to provide your contact information to the study staff.
If the staff is not able to reach you, they may try to locate you through telephone directory assistance or the internet. If the study staff is still unable to locate you, they may use a locator service, such as Transunion or the National Change of Address (NCOA) database, which is maintained by the United States Postal Service.
If you agree to take part in this study, you will be asked to come to the Behavioral Science Research Clinic at M. D. Anderson for up to 2 laboratory sessions. One session will be while you are smoking, and one session will be while you are abstinent from smoking (not smoking).
At each of these sessions, you will have functional magnetic resonance imaging (fMRI) of your brain while you are looking at slides. fMRI involves a scanner that uses a large magnet, instead of x-rays, to take pictures of the inside of your body. The slides will include pictures of people, nature scenes, artwork, victims of car crashes, medical procedures (such as open surgery or autopsy), and nude people. You will be shown examples of these slides before having the fMRI, and you will be given the opportunity to withdraw from this study at that time. If you choose to continue on this study, you will have an fMRI taken of your brain. This will involve being passed into a narrow tube-shaped scanner that is open at both ends. During the fMRI, your brain electrical activity will be monitored. The total time for each lab session will last about 1.5 hours.
You should not drink more than 2 cups of coffee or other caffeine drinks at least 2 1/2 hours before each session. This is because caffeine may affect brain functioning. Before one or both of your sessions, you may be asked to not smoke from bedtime on the day before the session until after the session on the next day. Before one or both of your sessions, you may be asked to smoke as you would regularly. Additionally, you may be asked to smoke during one or both of your laboratory sessions.
At each lab session, you will be asked to blow air through a carbon monoxide (CO) measuring device. CO is a gas that is found (in higher levels) in the bodies of cigarette smokers. You will also be asked questions about your smoking habits; your health and medical condition; and about any medications you are taking. You will also be asked to complete some questionnaires that will ask about your mood and feelings. You may be asked to complete these questionnaires before, during, or after the fMRI.
At the end of this study, you will be able to ask questions about the results of this study and about procedures you have experienced during this study.
Your participation in this part of the study will last about 2 weeks. It will end after your last lab session. You will still be considered a participant in the main study (Protocol 2003-1024) and may have additional visits, questionnaires, and other activities to complete.
This is an investigational study. Up to 72 participants will take part in this study. All will be enrolled at M.D. Anderson.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Paul Cinciripini, PhD | 713-792-0919 |
United States, Texas | |
U.T. M.D. Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Principal Investigator: Paul Cinciripini, PhD |
Principal Investigator: | Paul 713-792-0919, PhD | U.T. M.D. Anderson Cancer Center |
Responsible Party: | U.T. M.D. Anderson Cancer Center ( Paul Cinciripini, PhD/Professor ) |
Study ID Numbers: | 2005-0829 |
Study First Received: | April 21, 2008 |
Last Updated: | December 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00664404 |
Health Authority: | United States: Institutional Review Board |
Smoking Smoking Cessation Nicotine Withdrawal Nicotine Dependence |
Neuroregulatory Effects Magnetic Resonance Imaging MRI |
Nicotine polacrilex Smoking Substance Withdrawal Syndrome Nicotine |
Mental Disorders Substance-Related Disorders Disorders of Environmental Origin |
Habits Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cholinergic Agonists Autonomic Agents Nicotinic Agonists |
Physiological Effects of Drugs Ganglionic Stimulants Peripheral Nervous System Agents Cholinergic Agents Pharmacologic Actions |